Comparative evaluation of lumpy skin disease virus-based live atenuated vaccines

dc.contributor.authorHaegeman, Andy
dc.contributor.authorDe Leeuw, Ilse
dc.contributor.authorMostin, Laurent
dc.contributor.authorVan Campe, Willem
dc.contributor.authorAerts, Laetitia
dc.contributor.authorVenter, Estelle Hildegard
dc.contributor.authorTuppurainen, Eeva
dc.contributor.authorSaegerman, Claude
dc.contributor.authorDe Clercq, Kris
dc.date.accessioned2022-05-05T06:10:44Z
dc.date.available2022-05-05T06:10:44Z
dc.date.issued2021-05
dc.description.abstractVaccines form the cornerstone of any control, eradication and preventative strategy and this is no different for lumpy skin disease. However, the usefulness of a vaccine is determined by a multiplicity of factors which include stability, efficiency, safety and ease of use, to name a few. Although the vaccination campaign in the Balkans against lumpy skin disease virus (LSDV) was successful and has been implemented with success in the past in other countries, data of vaccine failure have also been reported. It was therefore the purpose of this study to compare five homologous live attenuated LSDV vaccines (LSDV LAV) in a standardized setting. All five LSDV LAVs studied were able to protect against a challenge with virulent LSDV. Aside from small differences in serological responses, important differences were seen in side effects such as a local reaction and a Neethling response upon vaccination between the analyzed vaccines. These observations can have important implications in the applicability in the field for some of these LSDV LAVs.en_US
dc.description.departmentVeterinary Tropical Diseasesen_US
dc.description.librarianpm2022en_US
dc.description.sponsorshipThe Bill & Melinda Gates Foundation, the GALVmed project Nr CAO-R34A0856 on lumpy skin disease and the Belgian Federal Public Service of Health, Food Chain Safety and Environment through the contract RT 15/3 (LUMPY SKIN 1).en_US
dc.description.urihttp://www.mdpi.com/journal/vaccinesen_US
dc.identifier.citationHaegeman, A.; De Leeuw, I.; Mostin, L.; Campe, W.V.; Aerts, L.; Venter, E.; Tuppurainen, E.; Saegerman, C.; De Clercq, K. Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines. Vaccines 2021, 9, 473. https://doi.org/10.3390/vaccines9050473.en_US
dc.identifier.issn2076-393X (online)
dc.identifier.other10.3390/ vaccines9050473
dc.identifier.urihttps://repository.up.ac.za/handle/2263/85069
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rights© 2021 by the authors. Licensee: MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en_US
dc.subjectVaccine evaluationen_US
dc.subjectLive attenuated vaccinesen_US
dc.subjectLumpy skin disease vaccineen_US
dc.subjectLumpy skin disease virus (LSDV)en_US
dc.titleComparative evaluation of lumpy skin disease virus-based live atenuated vaccinesen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Haegeman_Comparative_2021.pdf
Size:
3.25 MB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Haegeman_ComparativeSuppl_2021.pdf
Size:
642.03 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Material

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: